Profusa Partners with Mayo Clinic to Expand Oxygen Monitoring Tech Applications
Event summary
- Profusa and Mayo Clinic entered a know-how agreement on February 12, 2026, to advance clinical applications of oxygen monitoring technologies.
- The collaboration aims to accelerate regulatory approval and commercialization of Profusa’s Lumee™ wearable continuous tissue oxygen monitoring product.
- Target indications include cardiovascular, renal, multi-organ, and orthopedic applications, with a focus on postoperative perfusion monitoring.
- Mayo Clinic has a financial interest in the technology and will use any revenue to support its not-for-profit mission in patient care, education, and research.
The big picture
This collaboration marks a strategic move to validate and expand the clinical utility of Profusa’s oxygen monitoring technology. The partnership with Mayo Clinic, a leader in medical research and patient care, could accelerate the adoption of Lumee™ and other products in high-impact clinical areas. The focus on postoperative perfusion monitoring aligns with broader industry trends toward personalized medicine and earlier disease detection.
What we're watching
- Regulatory Approval
- The pace at which Profusa can secure regulatory approval for Lumee™ in the U.S. will determine the timeline for commercialization.
- Market Expansion
- Whether Profusa can successfully expand its oxygen monitoring technology into new clinical indications beyond critical limb ischemia.
- Execution Risk
- How Profusa’s ability to leverage Mayo Clinic’s expertise will impact the development and commercialization of new products.
Related topics